



Maryland Technology Development Corporation and [Toucan Capital Corporation](#) Hosts

**Innovations in Drug Discovery, Delivery and Diagnostics for  
Neurodegenerative and Psychiatric Diseases**

*Featuring National Institutes of Health technologies from:  
NINDS, NIDA, NIA, NIDCR, NIMH*

|                           |   |
|---------------------------|---|
| <b>8:00 am – 9:00 am</b>  | <b>Registration and Continental Breakfast</b>   |
| <b>9:00 am – 9:15 am</b>  | <b>Opening Remarks</b><br>Dr. Phillip Singerman, Executive Director Maryland Technology Development Corp. (TEDCO)<br>Mark Rohrbaugh, Director, NIH Office of Technology Transfer<br>Richard Nakamura, Deputy Director, National Institute of Mental Health (NIMH)   |
| <b>9:15 am – 9:25 am</b>  | <b>Case Study</b><br>Dr. Bruce Weintraub, COO and Chief Scientific Officer, Trophogen   |
| <b>9:25 am – 10:15 am</b> | <b>Session I Presentations</b><br><b>Growth factor production using an immortalized human brain cell</b><br>Dr. Eugene Major, National Institute of Neurological Disorders and Stroke (NINDS), Chief of the Laboratory of Molecular Medicine and Neuroscience <ul style="list-style-type: none"> <li>• A method for treating a variety of neurological disorders and brain tumors using immortalized astrocytes.</li> <li>• Cells may be given DNA which produce active peptides</li> <li>• Cells have been successfully implanted in the central nervous system in animal models</li> </ul> <b>Biomarker for diagnosis of MS</b><br>Dr. Roland Martin, NINDS, Cellular Immunology Section, Neuroimmunology Branch<br><b>Novel Dopaminergic Agents for Neuropsychiatric Disorders and Drug Abuse</b><br>Dr. Amy Newman, National Institute for Drug Abuse (NIDA), Medications Discovery Research Branch <ul style="list-style-type: none"> <li>• The dopamine D3 receptor has been implicated in drug abuse, schizophrenia and Parkinson's disease</li> <li>• A family of potent selective D3 receptor antagonists with higher bioavailability</li> </ul> <b>A genetics-based approach to understanding and treating neurodegenerative disease</b><br>Dr. John Hardy, National Institute on Aging (NIA), Lab of Neurogenetics<br><b>Development of lentiviral vectors for gene discovery and gene therapy</b><br>Dr. Zhennan Lai, NINDS, Developmental and Metabolic Neurology Branch <ul style="list-style-type: none"> <li>• Lentiviral vectors overcome immune response problem in the host</li> <li>• Vectors can express two separate gene products in a single cell</li> <li>• Biologically functional gene products are delivered to both infected and neighboring non-infected cells</li> </ul> <b>Use of RNAi to treat chemotherapy-resistant malignant gliomas</b><br>Dr. John Park, NINDS, Surgical and Molecular Neuro-oncology Unit <ul style="list-style-type: none"> <li>• Delivery of stathmin RNAi oligonucleotides alone or with standard chemotherapies</li> <li>• Potential treatments for brain and lung tumors and for leukemias</li> </ul> <b>Methods of identifying and treating tumors that express erythropoietin</b> |

|                            |  |
|----------------------------|--|
|                            | <p><b>receptor protein</b><br/>Dr. Zhengping Zhuang, NINDS, Clinical Neurosurgery Branch</p> <ul style="list-style-type: none"> <li>• Von Hippel-Lindau disease associated tumors of the CNS, pancreas, kidney and other organs co-express erythropoietin (Epo) and erythropoietin receptor proteins (EpoR)</li> <li>• EpoR may be useful as a diagnostic and therapeutic target</li> </ul> <p><b>Convection Enhanced Delivery (CED) in Neurological Drug Delivery</b><br/>Dr. John Heiss, NINDS, Clinical Neurosurgery Department, Surgical Neurology Branch</p> <ul style="list-style-type: none"> <li>• Unique marker for tracking and verification of drug delivery to the CNS</li> <li>• Use of convection delivery techniques for drug delivery to the CNS is guesswork without use of a proven surrogate marker.</li> </ul>   |
| <b>10:15 am – 10:30 am</b> | <p><b>TEDCO Funding Presentation</b><br/>Dr. Steve Fritz, Director of Technology Transfer, Maryland Technology Development Corporation (TEDCO)</p>   |
| <b>10:30 am – 10:45 am</b> | <p><b>Break: Networking and Poster Sessions</b></p>  |
| <b>10:45 am – 11:35 am</b> | <p><b>Session II Presentations</b></p> <p><b>AAV vectors: Platform for efficient drug delivery to the CNS</b><br/>Dr. Jay Chiorini, National Institute of Dental and Craniofacial Research (NIDCR), Gene Therapy and Therapeutics Branch</p> <ul style="list-style-type: none"> <li>• AAV vectors provide continuous source of therapeutic proteins to tissue</li> <li>• Specific vectors provide for gene transfer into brain tissue</li> </ul> <p><b>HIV Dependent Viral Vector</b><br/>Dr. Jon Marsh, NIMH, Laboratory of Molecular Biology</p> <ul style="list-style-type: none"> <li>• HIV, is a retrovirus that infects brain cells as well as immune cells</li> <li>• All studies of HIV replication, require the measurement of HIV infectivity</li> <li>• A novel genetic construct</li> </ul> <p><b>Inhibiting neuronal apoptosis with protein based delivery of Bcl-xL</b><br/>Dr. Richard Youle, NINDS, Biochemistry Section, Surgical Neurology Branch</p> <ul style="list-style-type: none"> <li>• A Bcl-XL delivery system that prevents neuron cell death in animal</li> <li>• Therapeutic benefit for stroke and spinal cord injuries</li> </ul> <p><b>Advances in Expression Profiling</b><br/>Dr. Robert B. Innis, NIMH, Molecular Imaging Branch</p> <ul style="list-style-type: none"> <li>• Use of positron emission tomography (PET) in therapeutic drug development</li> <li>• Radio labeled probes of receptors can be used with therapeutic candidates to provide information on drug dosing, dosing intervals, and</li> </ul> |

|                            |   |
|----------------------------|---|
|                            | <p>efficacy</p> <p><b>Modulators of Nuclear Hormone Receptor Activity: Novel Compounds, Diverse Applications for Infectious Diseases, Including Anthrax (B. anthracis)</b></p> <p>Dr. Esther M. Sternberg, NIMH, Neuroendocrine Immunology and Behavior</p> <ul style="list-style-type: none"> <li>• Nuclear hormones protect against inflammatory diseases such as septic shock</li> <li>• Anthrax factor at a low level blocks the receptor for nuclear hormones</li> <li>• Drugs designed to prevent this could have be important for anthrax and for other inflammatory disease.</li> </ul> |
| <b>11:35 am – 11:50 am</b> | <b>Toucan Presentation</b><br>Linda Powers, Toucan Capital Corporation Managing Director  |
| <b>11:50 am – 12:20 pm</b> | <b>Lunch</b>  |
| <b>12:20 pm – 1:00 pm</b>  | <b>Panel Discussion and Q&amp;A Technology Collaboration with NIH</b><br><u>Topics and Panelists</u><br><b>Licensing:</b> Steven Ferguson, Office of Technology Transfer<br><b>Clinical Trials :</b> Linda Brady, NIMH<br><b>CRADAs:</b> Kathleen Carroll, NCI  |
| <b>1:00 pm – 1:30 pm</b>   | <b>Networking and Poster Sessions</b>   |

[Return to Overview](#)

[Register Now for this Exciting Showcase](#)

### *Showcase Outreach Partners*

- [ASM Resources, Inc.](#)
- [Bio-Tech Life 2004](#)
- [City of Frederick Department of Economic Development](#)
- [Dingman Center for Entrepreneurship, University of Maryland College Park](#)
- [Federal Laboratory Consortium](#)
- [Frederick County Office of Economic Development](#)
- [Greater Baltimore Technology Council](#)
- [MD Bio](#)
- [Maryland Business Incubation Association](#)
- [Maryland Department of Business and Economic Development](#)
- [Maryland Technology Extension Service](#)
- [Maryland Technology Development Center](#)
- [Maryland Technology Partnership for Innovation](#)
- [Montgomery County Department of Economic Development](#)
- [Rockville Economic Development, Inc.](#)
- [Scheer Partners](#)
- [Technology Council of Maryland](#)
- [Women In Bio](#)

